Table 5.12Incremental costs and effectiveness by treatment strategy for solid tumour patients who can not take quinolone (baseline risk of neutropenic sepsis of one course of chemotherapy: 34.41%)

StrategyTotal costs (£)Total QALYsIncremental costs (£)Incremental QALYsICER (£) versus baseline (QALYs)ICER (£) incremental (QALYs)
Nothing/Placebo£473.9-2.3*10-3——ComparatorComparator
Secondary prophylaxis with PEG-G-CSF£773.6-1.8*10-3£299.74.7*10-4£0.6 million£0.6 million
Secondary prophylaxis with G(M)-CSF£898.3-2.0*10-3£424.32.4*10-4£1.8 millionDominated
Primary prophylaxis with PEG-G-CSF£2170.2-5.6*10-4-£1,696.31.7*10-3£1.0 million£1.0 million
Primary prophylaxis with G(M)-CSF£2826.9-1.3*10-3£2352.99.2*10-4£2.6 millionDominated

From: 5, Reducing the risk of septic complications of anticancer treatment

Cover of Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients
Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients.
NICE Clinical Guidelines, No. 151.
National Collaborating Centre for Cancer (UK).
Copyright © National Collaborating Centre for Cancer, 2012.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.